The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
J Natl Compr Canc Netw. 2019 Nov;17(11.5):1424-1426
Authors: Zelenetz AD
Abstract
Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim-sndz, bevacizumab-awwb, trastuzumab-dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.
PMID: 31766021 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Filgrastim | Hematology | Herceptin | Neulasta | Neupogen | Politics | Rituxan | USA Health